Seeking opportunities to be more inclusive can help pharma companies gain a deeper understanding of key opinion leader and patient perspectives and build diversity into the entire product journey.
With treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.
The highly-regulated pharmaceutical industry poses serious challenges that can derail digital health programs. But, there are solutions.
Multiple regulatory pathways exist during the drug development process.
Medical science liaisons (MSL) in the pharma industry were already at their limit pre-COVID. The challenge for MSLs is to identify the most efficient way to upskill their teams and add digital competencies without overloading them.
Recognition of the business case for ESG in pharma is soaring.
A five-step pilot approach to effective measurement of medical affairs omnichannel efforts.
A recent industry-wide survey reveals disconnects and unmet needs pertaining to real-world patient data and analytics that can impact business decision making.
As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
Pandemic workforce trends continue to create challenges for pharma.
*** Time and Date: Tuesday, November 17 I 11:00 am – 2:30 pm EST *** *** On-demand available after final airing until Nov. 17, 2021***
With a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.
Delivering value with enterprise program management.
As healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.
COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
How pharma companies can make justice and integrity a priority.
Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Owning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.